tbuckley/cabot-search huggingface dataset:
Prospective Observational Study of Sentinel Lymphadenectomy Without Further Axillary Dissection in Patients With Sentinel Node–Negative Breast Cancer
Authors: Armando E. Giuliano, Philip I. Haigh, Meghan B. Brennan, Nora M. Hansen, Mark C. Kelley, Wei Ye, Edwin C. Glass, Roderick R. Turner
Journal: Journal of Clinical Oncology (2000)

PURPOSE: Immediate complete axillary lymphadenectomy (ALND) after sentinel lymphadenectomy (SLND) has confirmed that tumor-negative sentinel nodes accurately predict tumor-free axillary nodes in breast cancer. Therefore, we hypothesized that SLND alone in patients with tumor-negative sentinel nodes would achieve axillary control, with minimal complications. PATIENTS AND METHODS: Between October 1995 and July 1997, 133 consecutive women who had primary invasive breast tumors clinically ≤ 4 cm in diameter and no axillary lymphadenopathy were prospectively entered onto a trial of SLND using vital blue dye. Sentinel nodes were examined by standard microscopy or immunohistochemistry. SLND was the only axillary surgery if sentinel nodes were tumor-free. Completion ALND was performed only if sentinel nodes contained metastases or if they were not identified. Excluded from subsequent analysis were patients with unsuspected multifocal carcinoma and those who refused completion ALND. The complication and axillary recurrence rates after SLND without ALND were determined. RESULTS: Sentinel nodes were identified in 132 (99%) of 133 patients. Eight patients were excluded from further analysis. Of the 125 assessable patients, 57 had tumor-positive sentinel nodes and one had an unsuccessful mapping procedure; these patients underwent completion ALND. In the remaining 67 patients (54%), SLND was the only axillary procedure. Complications occurred in 20 patients (35%) undergoing ALND after SLND but in only two patients (3%) undergoing SLND alone (P = .001). There were no local or axillary recurrences at a median follow-up of 39 months. CONCLUSION: Complication rates are negligible after SLND alone. An absence of axillary recurrences supports SLND as an accurate staging alternative for breast cancer and suggests that routine ALND can be eliminated for patients with histopathologically negative sentinel nodes.
Isolation of Transforming and Early Antigen-Inducing Epstein-Barr Virus From Nasopharyngeal Carcinoma Hybrid Cells (NPC-KT)
Authors: T Takimoto, H Ogura, H Sato, R Umeda, M Hatano
Journal: JNCI Journal of the National Cancer Institute (1985)

The biologic activities of Epstein-Barr (EB) virus from an epithelioid-nasopharyngeal carcinoma hybrid cell line (NPC-KT) and three subclones from the NPC-KT cells were examined. Much infectious virus was released by treatment with 5-iodo-2#x2032;-deoxyuridine. All virus preparations from NPC-KT cells and the subclones were found to possess both transforming and EB virus-induced early antigen (EA)-inducing activities. The lymphoblastoid cell lines, which were established by infection of human cord-blood lymphocytes with the virus, were diploid with normal karyotypes. The cell lines were positive for EB virus-associated nuclear antigen but negative for EA and EB viral capsid antigen.
Transfusion-transmitted virus infection in HIV-1-seropositive patients
Authors: M. Debiaggi, F. Zara, P. Sacchi, R. Bruno, M. Mazzucco, R. Poma, F. Raffaldi, L. Gerace, M. Perini, A. Pistorio, E. Romero, G. Filice
Journal: Clinical Microbiology and Infection (2000)
Diagnostic impact of EUS(b)-FNA in diagnostics of sarcoidosis
Authors: Ilya Sivokozov, Olga Lovacheva, Irina Shumskaya, Galina Evgushenko, Larisa Lepekha
Journal: European Respiratory Journal (2013)

RATIONALE. Endosonography with fine-needle aspiration (EUS-FNA) became a promising method of choice for sarcoidosis, but still data regarding the contribution of EUS-FNA on final efficacy of endoscopic diagnostics are sparse. METHODS. 45 patients with suspicion for sarcoidosis (stage II) undergone a bronchoscopy with TBLB via right middle lobe, and subsequent EUS-FNA (via esophagus) using Olympus ultrasound bronchoscope with 22G needle. All EUS-FNAs were performed for lymph nodes stations 7 or 4L (3 passes per node and procedure). Diagnostic yield by histology and cytology for FNA and TBLB specimens were analyzed.  RESULTS There were no complications for all biopsies. For TBLBs both histology and cytology specimens were obtained, median number of biopsies was 3. Diagnosis was confirmed by TBLB in 31/45 (69%) pts via histology, and in 14/45 pts (31%) by cytology. Cumulative efficacy of TBLB reached 34/45 (78%) pts. EUS-FNA reached an adequate cytology specimens in all cases, histology specimens were obtained only in 2/45 (4%) pts, informative material was received in 38/45 (84%) pts. Two histology specimens also were informative. The whole efficacy of EUS-FNA reached 38/45 (84%) pts. Totally, TBLB and EUS-FNA gave confirmation of disease in 41/45 (91%) pts. Difference between TBLB and EUS-FNA groups for total diagnostic yield (78% and 84% for TBLB and EUS-FNA, respectively; p>0.05) was non-significant, but cytological yield favored EUS-FNA (31% and 84% for TBLB and EUS-FNA, respectively; p  CONCLUSION. According to our data, endoscopic ultrasound-guided FNA makes substantial contribution in confirmation of disease in sarcoidosis patients.
PLA2 polymorphism of platelet glycoprotein IIb/IIIa but not Factor V Leiden and prothrombin G20210A polymorphisms is associated with venous thromboembolism and more recurrent events
Authors: Hamid Rouhi Boroujeni, Batoul Pourgheysari, Ali Hasheminia
Journal: European Respiratory Journal (2012)

Introduction: Inherited thrombophilic gene polymorphisms have been linked to the pathogenesis of venous thromboembolism (VTE). As they are very limited data of these polymorphisms in Iranian population we aimed to investigate them in these patients.

Methods: 72 patients with VTE and 306 healthy control subjects were recruited to the study. Genotyping from EDTA taken venous blood for the factor V Leiden (FVL), prothrombin (FII) G20210A, methylene tetrahydrofolate reductase (MTHFR) C677T and PLA2 polymorphisms was under taken by PCR – RFLP.

Results: 57of investigated polymorphisms with the mean of 0.792 per individual and 151 with the mean of 0.494 were found in patients and control respectively (p<0.001). FVL and FII G20210A were found in 5.6% and 1.4% of the patients compared with 2.3% and 1% of the controls respectively (P=NS). PLA2 polymorphism of GPIIb/IIIa was seen in 27.8% and 10.1% in patients and controls respectively (OR=3.4, CI= 1.08-6.44, P<0.001). 21.5% of carrier VTE patients compared with 9.6% of carrier controls had coinheritance of more than one genetic risk factor (P=0.007) and more recurrent events were occurred in them. Patients with PLA2 polymorphism had more recurrent events than the other patients (P=0.02). Patients with more than one genetic risk factors and recurrent events were younger.

Discussion: Higher prevalence of PLA2 polymorphism of GPIIa/IIIb in VTE patients demonstrates the impact of this polymorphism in the pathogenesis of VTE in this population that need to manage these patiant differently.
Total respiratory resistance and reactance in patients with diffuse interstitial lung disease
Authors: J A van Noord, J Clément, M Cauberghs, I Mertens, K P Van de Woestijne, M Demedts
Journal: European Respiratory Journal (1989)

In 54 patients with interstitial lung diseases and no signs of airway obstruction we measured lung volumes, maximal expiratory flows, diffusing capacity (DLCO), total respiratory resistance (Rrs) and reactance (Xrs) between 4 and 26 Hz by means of the forced oscillation technique. In all patients DLCO was less than 75% of the expected value. Patients were classified into two groups depending on total lung capacity (TLC): group A with TLC less than 80% of expected, and group B with TLC of 80% or more. Group A demonstrated a decrease of Xrs especially at low frequencies, with small, not significant changes in Rrs. In the patients in this group with the lowest values of TLC (less than 50%), we observed an increase of Rrs at low frequencies causing a negative frequency dependence of Rrs. In group B no distinct changes of Rrs and Xrs occurred. Canonical correlation analysis between routine lung function data and forced oscillation parameters, showed tight correlations between TLC in absolute value or VC in percent of the predicted value on the one hand and average level of Xrs and average slope of Xrs (and Rrs) vs frequency curves on the other hand. Measurements of lung mechanics in five additional patients and comparison with a model of the respiratory system suggest that the changes of Rrs and Xrs are not explained totally by the observed increase in lung tissue resistance and decrease in lung compliance. The observed changes in Rrs and Xrs are not specific for restrictive lung disorders; similar changes are met also in moderately advanced obstructive diseases.
The cAMP-producing agonist beraprost inhibits human vascular smooth muscle cell migration via exchange protein directly activated by cAMP
Authors: Jenny S. McKean, Fiona Murray, George Gibson, Derryck A. Shewan, Steven J. Tucker, Graeme F. Nixon
Journal: Cardiovascular Research (2015)

During restenosis, vascular smooth muscle cells (VSMCs) migrate from the vascular media to the developing neointima. Preventing VSMC migration is therefore a therapeutic target for restenosis. Drugs, such as prostacyclin analogues, that increase the intracellular concentration of cyclic adenosine monophosphate (cAMP) can inhibit VSMC migration, but the mechanisms via which this occurs are unknown. Two main downstream mediators of cAMP are protein kinase A (PKA) and exchange protein directly activated by cAMP (Epac). This study has examined the effects of the prostacyclin analogue beraprost on VSMC migration and investigated the intracellular pathways involved. In a chemotaxis chamber, human saphenous vein VSMC migrated towards a platelet-derived growth-factor-BB (PDGF) chemogradient. Incubation with therapeutically relevant concentrations of cAMP-producing agonist beraprost significantly decreased PDGF-induced migration. Direct activation of either PKA or Epac inhibited migration whereas inhibition of PKA did not prevent the anti-migratory effect of beraprost. Direct activation of Epac also prevented hyperplasia in ex vivo serum-treated human veins. Using fluorescence resonance energy transfer, we demonstrated that beraprost activated Epac but not PKA. The mechanisms of this Epac-mediated effect involved activation of Rap1 with subsequent inhibition of RhoA. Cytoskeletal rearrangement at the leading edge of the cell was consequently inhibited. Interestingly, Epac1 was localized to the leading edge of migrating VSMC. These results indicate that therapeutically relevant concentrations of beraprost can inhibit VSMC migration via a previously unknown mechanism involving the cAMP mediator Epac. This may provide a novel target that could blunt neointimal formation.
A Novel p53/microRNA‐22/Cyr61 Axis in Synovial Cells Regulates Inflammation in Rheumatoid Arthritis
Authors: Jinpiao Lin, Rongfen Huo, Lianbo Xiao, Xianjin Zhu, Jun Xie, Songtao Sun, Yong He, Jie Zhang, Yue Sun, Zhou Zhou, Pinru Wu, Baihua Shen, Dangsheng Li, Ningli Li
Journal: Arthritis & Rheumatology (2013)

We previously showed that Cyr61 acts to promote fibroblast-like synoviocyte (FLS) proliferation and Th17 cell differentiation, suggesting that Cyr61 plays an important role in mediating the joint inflammation and damage in rheumatoid arthritis (RA). The aim of this study was to investigate whether Cyr61 expression is regulated at the posttranscription level, and if so, how this regulation connects to other etiologic factors in RA.Expression of microRNA-22 (miR-22) in synovial tissue was detected by real-time polymerase chain reaction (PCR) using miRNA-specific TaqMan MGB probes. MicroRNA-22 promoter activity was analyzed using a Dual-Luciferase Reporter Assay. Cytokine expression was measured by enzyme-linked immunosorbent assay, and the expression of other factors was measured by real-time PCR or Western blotting.MicroRNA-22 directly targeted the 3'-untranslated region of Cyr61 messenger RNA and inhibited Cyr61 expression. Expression of miR-22 was down-regulated and was negatively correlated with Cyr61 expression in RA synovial tissue. Furthermore, wild-type p53 activated miR-22 transcription by binding to the promoter region of the miR-22 gene, while the mutant forms of p53 frequently found in RA synovial tissue were shown to have lost the ability to activate miR-22 expression. As a result, miR-22 was down-regulated, contributing to the overexpression of Cyr61 in RA FLS.Our results not only reveal a novel mechanism whereby p53 is involved in the posttranscriptional regulation of Cyr61 expression via miRNA-22, but also provide a molecular explanation for the role of somatic mutations of p53, which are frequently observed in RA synovial tissue, in the etiology of this autoimmune disease.
Abstract 4291: A novel image-based cytometry method for autophagy detection in living cells
Authors: Leo Li-Ying Chan, Dee Shen, Alisha R. Wilkinson, Wayne Patton, Ning Lai, Eric Chan, Dmitry Kuksin, Bo Lin, Jean Qiu
Journal: Cancer Research (2014)

Abstract Autophagy is an important cellular catabolic process that plays a variety of important roles, including maintenance of the amino acid pool during starvation, recycling of damaged proteins and organelles, and clearance of intracellular microbes. Currently employed autophagy detection methods include fluorescence microscopy, biochemical measurement, SDS-PAGE, and Western blotting, but they are time-consuming, labor-intensive, and require much experience for accurate interpretation. More recently, development of novel fluorescent probes have allowed the investigation of autophagy via standard flow cytometry. However, flow cytometers remain relatively expensive and require a considerable amount of maintenance. Previously, image-based cytometry has been shown to perform automated fluorescence-based cellular analysis comparable to flow cytometry. In this study, we developed a novel method using the Cellometer image-based cytometer in combination with Cyto-ID® Green dye for autophagy detection in live cells. The method is compared to flow cytometry by measuring macroautophagy in nutrient-starved Jurkat cells. Results demonstrate similar trends of autophagic response, but different magnitude of fluorescence signal increases, which may arise from different analysis approaches characteristic of the two instrument platforms. The possibility of using this method for drug discovery applications is also demonstrated through the measurement of dose-response kinetics upon induction of autophagy with rapamycin and tamoxifen. The described image-based cytometry/fluorescent dye method should serve as a useful addition to the current arsenal of techniques available in support of autophagy-based drug discovery relating to various pathological disorders. Citation Format: Leo Li-Ying Chan, Dee Shen, Alisha R. Wilkinson, Wayne Patton, Ning Lai, Eric Chan, Dmitry Kuksin, Bo Lin, Jean Qiu. A novel image-based cytometry method for autophagy detection in living cells. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4291. doi:10.1158/1538-7445.AM2014-4291
Alcohol Consumption and the Risk of Type 2 Diabetes: A Systematic Review and Dose-Response Meta-analysis of More Than 1.9 Million Individuals From 38 Observational Studies
Authors: Craig Knott, Steven Bell, Annie Britton
Journal: Diabetes Care (2015)

OBJECTIVE Observational studies indicate that moderate levels of alcohol consumption may reduce the risk of type 2 diabetes. In addition to providing an updated summary of the existing literature, this meta-analysis explored whether reductions in risk may be the product of misclassification bias. RESEARCH DESIGN AND METHODS A systematic search was undertaken, identifying studies that reported a temporal association between alcohol consumption and the risk of type 2 diabetes. No restrictions were placed upon the language or date of publication. Non-English publications were, where necessary, translated using online translation tools. Models were constructed using fractional polynomial regression to determine the best-fitting dose-response relationship between alcohol intake and type 2 diabetes, with a priori testing of sex and referent group interactions. RESULTS Thirty-eight studies met the selection criteria, representing 1,902,605 participants and 125,926 cases of type 2 diabetes. A conventional noncurrent drinking category was reported by 33 studies, while five reported a never-drinking category. Relative to combined abstainers, reductions in the risk of type 2 diabetes were present at all levels of alcohol intake &amp;lt;63 g/day, with risks increasing above this threshold. Peak risk reduction was present between 10–14 g/day at an 18% decrease in hazards. Stratification of available data revealed that reductions in risk may be specific to women only and absent in studies that adopted a never-drinking abstention category or sampled an Asian population region. CONCLUSIONS Reductions in risk among moderate alcohol drinkers may be confined to women and non-Asian populations. Although based on a minority of studies, there is also the possibility that reductions in risk may have been overestimated by studies using a referent group contaminated by less healthy former drinkers.
Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion.
Authors: Eun-Ju Lee, Cristian Mircean, Ilya Shmulevich, Huamin Wang, Jinsong Liu, Antti Niemistö, John J Kavanagh, Je-Ho Lee, Wei Zhang
Journal: Molecular Cancer (2005)

Insulin-like growth factor binding protein 2 (IGFBP2) is overexpressed in ovarian malignant tissues and in the serum and cystic fluid of ovarian cancer patients, suggesting an important role of IGFBP2 in the biology of ovarian cancer. The purpose of this study was to assess the role of increased IGFBP2 in ovarian cancer cells.Using western blotting and tissue microarray analyses, we showed that IGFBP2 was frequently overexpressed in ovarian carcinomas compared with normal ovarian tissues. Furthermore, IGFBP2 was significantly overexpressed in invasive serous ovarian carcinomas compared with borderline serous ovarian tumors. To test whether increased IGFBP2 contributes to the highly invasive nature of ovarian cancer cells, we generated IGFBP2-overexpressing cells from an SKOV3 ovarian cancer cell line, which has a very low level of endogenous IGFBP2. A Matrigel invasion assay showed that these IGFBP2-overexpressing cells were more invasive than the control cells. We then designed small interference RNA (siRNA) molecules that attenuated IGFBP2 expression in PA-1 ovarian cancer cells, which have a high level of endogenous IGFBP2. The Matrigel invasion assay showed that the attenuation of IGFBP2 expression indeed decreased the invasiveness of PA-1 cells.We therefore showed that IGFBP2 enhances the invasion capacity of ovarian cancer cells. Blockage of IGFBP2 may thus constitute a viable strategy for targeted cancer therapy.
Maturation and Differentiation of B16 Melanoma Cells Induced by Theophylline Treatment2
Authors: John W. Kreider, David R. Wade, Murray Rosenthal, T. Densley
Journal: JNCI Journal of the National Cancer Institute (1975)

Journal Article Maturation and Differentiation of B16 Melanoma Cells Induced by Theophylline Treatment Get access John W. Kreider, John W. Kreider Search for other works by this author on: Oxford Academic PubMed Google Scholar David R. Wade, David R. Wade Search for other works by this author on: Oxford Academic PubMed Google Scholar Murray Rosenthal, Murray Rosenthal Search for other works by this author on: Oxford Academic PubMed Google Scholar T. Densley T. Densley Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 54, Issue 6, June 1975, Pages 1457–1467, https://doi.org/10.1093/jnci/54.6.1457 Published: 01 June 1975 Article history Received: 27 December 1974 Accepted: 24 February 1975 Published: 01 June 1975
Development of a new bronchial provocation test with dry powder adenosine
Authors: Erica van der Wiel, Anne Lexmond, Maarten van den Berge, Dirkje Postma, Anne de Boer, Nick ten Hacken
Journal: European Respiratory Journal (2013)

Introduction   Adenosine is an indirect stimulus to assess bronchial hyperresponsiveness (BHR), a hallmark of asthma. Bronchial provocation is usually performed with a solution of adenosine 5’-monophosphate (AMP) administered via a nebuliser. This nebulised AMP test has several disadvantages. It is a time-consuming method and AMP can be dissolved to a maximum concentration of 320 mg/ml resulting in BHR in only half of the asthma patients.   Aim   To develop a new provocation test using dry powder adenosine to assess BHR.   Methods   Dry powder adenosine was prepared in different dose steps (range 0.01 - 80 mg) derived from the regular AMP test with addition of 2 extra dose steps. Five patients with asthma performed two provocation tests; first a test with dry powder adenosine administered via a dry powder inhaler (Twincer tm  concept) and inhaled with a single slow inspiration (30 L/min); secondly a test with nebulised AMP according to the 2-minute tidal breathing method.   Results   All 5 patients reached a 20% fall in FEV 1  with the new dry powder adenosine test (PD 20 ) compared to 4 patients with the AMP test (PC 20 ).The AMP-negative patient reached a PD 20  after inhaling 80 mg of adenosine, a higher dose than the last step of 320 mg/ml (±28 mg) AMP. The new dry powder adenosine test was well tolerated by all patients and much easier and quicker to carry out than the regular AMP test.   Conclusion   The new dry powder adenosine provocation test appears to be a reliable and safe alternative for the regular AMP test to assess BHR in patients with asthma. The dry powder adenosine test has several improvements compared to the AMP test, i.e. lower burden on the patient and it allows provocation with higher dose steps.
Original article: Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma
Authors: H. Gurney, D. Crowther, H. Anderson, D. Murphy, J. Prendiville, M. Ranson, P. Mayor, R. Swindell, C.H. Buckley, V.R. Tindall
Journal: Annals of Oncology (1990)